Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where P. Spratt is active.

Publication


Featured researches published by P. Spratt.


Transplantation | 1995

Selective Inhibition Of Nitric Oxide Production During Cardiac Allograft Rejection Causes A Small Increase In Graft Survival

David Winlaw; Christopher G. Schyvens; George A. Smythe; Zu Y. Du; S. Rainer; Reginald S. A. Lord; P. Spratt; P. Macdonald

Nitric oxide production is increased in allograft rejection and may have both beneficial and deleterious effects on graft function and survival. In animal models, conventional immunosuppressive agents have been shown to decrease nitric oxide production. The aim of our study was to determine what effect augmentation and selective inhibition of nitric oxide production may have on graft survival by using the model of heterotopic cardiac transplantation in the rat. L-Arginine, the naturally occurring substrate for nitric oxide production, was administered subcutaneously at 200 mg/kg/day. L-NG-monomethyl-L-arginine (L-NMMA) is a selective inhibitor of nitric oxide synthase and was administered at 500 mg/kg/day to allograft recipients from the day of operation. Endogenous nitric oxide production was quantified by analysis of urinary nitrate excretion, and time to rejection was determined by graft palpation. L-Arginine did not significantly alter urinary nitrate excretion by iso- or allografts, suggesting that nitric oxide production is not a substrate-limited process in this model. Graft survival in this group was unchanged. L-NMMA produced a small increase in graft survival from 5.1 +/- 0.1 to 6.3 +/- 0.3 days compared with control allografts (P = 0.001) and abolished the rise in urinary nitrate excretion seen with control allografts. Lower doses of L-NMMA produced dose-related decrements in urinary nitrate excretion, but did not alter graft survival. We found that allograft rejection can proceed to graft loss despite complete inhibition of the increase in nitric oxide production that occurs during untreated rejection. The small increase in graft survival suggests that nitric oxide plays a minor role as a cytotoxic effector molecule in this model of acute rejection.


Pacing and Clinical Electrophysiology | 2009

Left Ventricular Mechanical Assist Devices and Cardiac Device Interactions: An Observational Case Series

David Foo; Bruce D. Walker; Dennis L. Kuchar; Charles W. Thorburn; Andre Tay; Christopher S. Hayward; P. Macdonald; Anne Keogh; E. Kotlyar; P. Spratt; P. Jansz

Background: Nonpulsatile left ventricular assist devices (LVADs) are increasingly used for treatment of refractory heart failure. A majority of such patients have implanted cardiac devices, namely implantable cardioverter‐defibrillators (ICDs) or cardiac resynchronization therapy‐pacemaker (CRT‐P) or cardiac resynchronization therapy‐defibrillator (CRT‐D) devices. However, potential interactions between LVADs and cardiac devices in this category of patients remain unknown.


Pacing and Clinical Electrophysiology | 2015

Impact of Implantable Cardioverter Defibrillators on Survival of Patients with Centrifugal Left Ventricular Assist Devices

William Lee; Andre Tay; Rajesh N. Subbiah; Bruce D. Walker; Dennis L. Kuchar; K. Muthiah; P. Macdonald; Anne Keogh; E. Kotlyar; Andrew Jabbour; P. Spratt; P. Jansz; Emily Granger; K. Dhital; Christopher S. Hayward

Both implantable cardioverter defibrillators (ICDs) and left ventricular assist devices (LVADs) have a positive impact on survival in the heart failure population. We sought to determine whether these positive effects on survival are additive or whether LVAD therapy supersedes ICD therapy.


Surgery Today | 2003

Pulmonary vein thrombosis treated successfully by thrombectomy after bilateral sequential lung transplantation: report of a case.

Itaru Nagahiro; Matthew Horton; Michael K. Wilson; Jayme Bennetts; P. Spratt; Allan R. Glanville

Abstract.We report the case of a 35-year-old man in whom an acute pulmonary vein thrombosis developed following bilateral sequential lung transplantation for cystic fibrosis. The thrombus was detected by transesophageal echocardiography 12 h after transplantation and an emergency thrombectomy was successfully performed.


Clinical and Experimental Pharmacology and Physiology | 1997

PAPAVERIVE ABOLISHES ENDOTHELIUM-DEPENDENT DILATATION OF HUMAN INTERNAL MAMMARY ARTERIES IN VITRO

Christopher G. Schyvens; Robert A. Owe-Young; P. Spratt; Mundy J; Alan Farnsworth; P. Macdonald

1. The purpose of the present study was to examine the effects of papaverine‐HCl, administered into the lumen of the human internal mammary artery (IMA) during harvesting of this vessel, on vascular reactivity in vitro and to specifically test the hypothesis that intraluminal administration of papaverine‐HCl impairs endothelium‐dependent vasodilation.


Journal of Heart and Lung Transplantation | 2001

Optimization of left ventricular function with carvedilol before high-risk cardiac surgery.

E. Kotlyar; P. Macdonald; Anne Keogh; Ruth H Arnold; Dermot J McCaffrey; Michael K. Wilson; P. Spratt

Patients with severe left ventricular dysfunction and symptomatic heart failure caused by ischemic or valvular heart disease face a high morbidity and mortality risk from cardiac surgery. We present data showing that excellent surgical outcome can be achieved after pre-treatment of such patients with carvedilol.


Journal of Heart and Lung Transplantation | 2001

Interventional bronchoscopy for the management of airway complications following lung transplantation

Prashant N. Chhajed; M.A. Malouf; Michael Tamm; P. Spratt; Allan R. Glanville

STUDY OBJECTIVES To assess the efficacy and complications of different interventional bronchoscopic techniques used to treat airway complications after lung transplantation. DESIGN Retrospective study. SETTING Heart-lung transplant unit of a university hospital. PATIENTS From November 1986 to January 2000, interventional bronchoscopy was performed in 41 of 312 lung transplant recipients (13.1%) for tracheobronchial stenosis, bronchomalacia, granuloma formation, and dehiscence. INTERVENTIONS Dilatation, stent placement, laser or forceps excision. MEASUREMENTS AND RESULTS Mean (+/- SE) improvement in FEV(1) in 26 patients undergoing dilatation for a stenotic or a combined lesion was 93 +/- 334 mL or 8 +/- 21%. In seven of these patients not proceeding to stent placement, mean improvement in FEV(1) was 361 +/- 179 mL or 21 +/- 9%. Patients needing stent placement after dilatation had a mean change in FEV(1) after dilatation of - 5 +/- 325 mL or 3 +/- 23%, and an improvement of 625 +/- 480 mL or 52 +/- 43% after stent insertion. Mean improvement in FEV(1) for patients treated with stent insertion for bronchomalacia was 673 +/- 30 mL or 81 +/- 24%. Complications of airway stents were migration (27%), mucous plugging (27%), granuloma formation (36%), stent fracture (3%), and formation of a false passage (6%). Mortality associated with interventional bronchoscopy was 2.4% (1 of 41 patients). For patients with airway complications successfully undergoing interventional bronchoscopy, the overall 1-year, 3-year, and 5-year survival rates were 79%, 45%, and 32%, respectively, vs 87%, 69%, and 56% for those without airway complications (p < 0.05). CONCLUSION Only a small number of patients with airway stenosis after lung transplantation will respond to bronchial dilatation alone. Patients with airway complications after lung transplantation have a higher mortality than patients without airway complications.


Internal Medicine Journal | 2017

Primary percutaneous coronary intervention for inferior ST‐segment elevation myocardial infarction in a patient supported by the HeartWare left ventricular assist device

Roberto Spina; Maithri Siriwardena; Nicole Bart; Mayooran Namasivayam; Mark Connellan; P. Jansz; P. Spratt; Christopher S. Hayward; E. Kotlyar; Brendan Gunalingam

A 63‐year‐old man with an ischaemic cardiomyopathy, supported by the HeartWare left ventricular assist device (LVAD), presented with ventricular tachycardia and inferior ST‐elevation myocardial infarction (STEMI) with associated acute right ventricular (RV) dysfunction. He underwent primary percutaneous coronary intervention with balloon angioplasty and placement of three drug‐eluting stents in the proximal‐to‐mid right coronary artery. Post‐procedure, ventricular arrhythmias abated, RV systolic dysfunction resolved and RV size normalised. Percutaneous coronary intervention (PCI) facilitated by the use of miniaturised percutaneous LVAD has become an increasingly available treatment option for high‐risk patients. PCI in patients on established full mechanical circulatory support is not a common occurrence. Indeed, to our knowledge, this is the first case of primary percutaneous coronary intervention on an LVAD‐supported heart reported in the medical literature. The case raises several specific issues that are of peculiar interest to clinicians involved in the care of patients supported by mechanical assist devices who experience an acute coronary syndrome requiring emergent revascularisation.


Journal of Heart and Lung Transplantation | 1996

Ischemic preconditioning enhances donor lung preservation in the rat.

Zu Ying Du; Mark Hicks; David Winlaw; P. Spratt; P. Macdonald


Journal of Heart and Lung Transplantation | 1998

Adjunctive use of inhaled nitric oxide during implantation of a left ventricular assist device.

P. Macdonald; Anne Keogh; Mundy J; Rogers P; Anthony Nicholson; Harrison Ga; P. Jansz; A. Kaan; P. Spratt

Collaboration


Dive into the P. Spratt's collaboration.

Top Co-Authors

Avatar

P. Jansz

St. Vincent's Health System

View shared research outputs
Top Co-Authors

Avatar

P. Macdonald

Victor Chang Cardiac Research Institute

View shared research outputs
Top Co-Authors

Avatar

Emily Granger

St. Vincent's Health System

View shared research outputs
Top Co-Authors

Avatar

E. Kotlyar

St. Vincent's Health System

View shared research outputs
Top Co-Authors

Avatar

Anne Keogh

St. Vincent's Health System

View shared research outputs
Top Co-Authors

Avatar

K. Dhital

St. Vincent's Health System

View shared research outputs
Top Co-Authors

Avatar

C. Hayward

St. Vincent's Health System

View shared research outputs
Top Co-Authors

Avatar

Andrew Jabbour

St. Vincent's Health System

View shared research outputs
Top Co-Authors

Avatar

D. Robson

St. Vincent's Health System

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge